{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"75","value":"13"},{"comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG001","lowerLimit":"8.5","upperLimit":"NA","value":"23.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Duration of major erythroid response (MER) is defined as the time interval between the documented date of MER and the earliest date of resumption of red blood cell transfusions ≥ 2 units in an 8-week period, a reduction in hemoglobin concentration ≥ 2 g/dL in the absence of acute infection, gastrointestinal bleeding and hemolysis, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21.","id":"OG000","title":"Arm A (Lenalidomide; Randomization)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.","id":"OG001","title":"Arm B (Lenalidomide + Epoetin Alfa; Randomization)"}],"paramType":"MEDIAN","populationDescription":"Only evaluable patients who achieved MER among randomized patients were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every cycle during treatment and then 3 and 6 months after last protocol treatment","title":"Duration of Major Erythroid Response (MER)","type":"SECONDARY","unitOfMeasure":"months"}